logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Trick or Trade?

The Misleading Market? The biotech stocks continue to begin their daily trading relying on opinionated articles implanted by bloggers on the Internet rather than on the firms’ voiced news.  It is unfortunate that we continue to observe many investors incapable...

Read More

April 26, 2019

0

The FDA Approval of Regeneron/Sanofi Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi s upplemental biological license application ( sBLA ) aimed at updating Praluent’s (alirocumab)  prescribing information is, indeed, a big deal. Proven life-saving benefits are confirmed. Comprising reducing...

Read More

April 30, 2019

0

Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children Good news for Vertex ( VRTX ) product  Kalydeco ®  (ivacaftor) is the first cystic fibrosis ( CF ) product to be prescribed for children ages six months to less than...

Read More

May 2, 2019

0

A Firm That Defied the Fierce Unwarranted Bear Market Day

Why GW Pharmaceuticals Survived the Bear Market Day The DOW Today Sinking for disputed and unfathomed reasons; watching and listening to analysts with antagonistic opinions on the TV screen; the stock market has taken down with it all the DOW...

Read More

May 7, 2019

0

Sanofi and Regeneron: Remarkable Results from Libtayo's Trial on Patients with Advanced Non-Small Cell Lung Cancer

Sanofi and Regeneron: Results from Libtayo® Trial Sanofi ( SNY ) and Regeneron ( REGN ) announced that the primary endpoint of overall survival ( OS ) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo®  (cemiplimab)...

Read More

April 27, 2020

0

Exelixis' and Daiichi Sankyo's Novel Antihypertensive Drug Minnebro® Hits the Japanese Market

Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan Exelixis ( EXEL )   and   Daiichi Sankyo  ( DSNKY )  Limited informed that Daiichi has launched their novel antihypertension product Minnebro ®  (esaxerenone) tablets in Japan. Exelixis ...

Read More

May 13, 2019

0

Compugen Has Encouraging News

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen ( CGEN ) announced that the first patient has been dosed in the Phase 1/2 study of the triple combination of COM701 - Compugen’s first-in-class anti-PVRIG antibody, with...

Read More

September 8, 2020

0

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy The United States Food and Drug Administration (FDA) has approved Regeneron’s ( REGN ) product EYLEA® (aflibercept) Injection for all stages of diabetic retinopathy . This approval...

Read More

May 14, 2019

0

Another Late-Stage Firm with Impressive Technology and Promising Products

About Iovance Biotherapeutics Iovance Biotherapeutics ( IOVA ) is   a late-stage biotechnology company developing novel cancer immunotherapies based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance announced promising updates from ongoing clinical trials in advanced cervical cancer and advanced melanoma...

Read More

May 16, 2019

0

The Medicines Company: Are Inclisiran's Clinical Trial Results Impressive?

The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results came out with several, not just one, good news.  Inclisiran's Good News The first good news  came from the ORION-3 study, conducted by The...

Read More

May 21, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 95
  • 96
  • 97
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy